1 ATLAS-2M is an ongoing, randomised,
multicentre (
13 countries; Australia, Argentina, Canada,
2 In this ongoing,
multicentre (
147 sites in 18 countries), open-label, non
3 , double-blind, active-controlled, phase-3b,
multicentre (
168 sites in 26 countries) trial enrolled p
4 This ongoing, randomised, double-blind,
multicentre,
active-controlled, phase 3, non-inferiority
5 This ongoing, randomised, double-blind,
multicentre,
active-controlled, phase 3, non-inferiority
6 udy is an ongoing, randomised, double-blind,
multicentre,
active-controlled, phase 3, non-inferiority
7 We did a
multicentre,
analyst-blinded, randomised controlled supe
8 cal data were collected through the European
Multicentre Bronchiectasis Audit and Research Collaborat
9 A
multicentre case-control study on women aged between 30
10 d predictors of neurodegeneration in a large
multicentre cohort of iRBD.
11 We did a prospective
multicentre cohort study across eight neonatal intensive
12 e Genetic Frontotemporal Dementia Initiative
multicentre cohort study collected between 2012 and 2018
13 oral Dementia Initiative (GENFI), which is a
multicentre cohort study of families with genetic fronto
14 It was a prospective
multicentre cohort study performed in five Brazilian ref
15 is is a nested case-control derived from the
multicentre cohort study Preterm SAMBA, in five differen
16 This
multicentre cohort study was done in Cote d'Ivoire, Demo
17 id Haemorrhage (GOSH) Study, a retrospective
multicentre cohort study with a median follow-up of 18 m
18 In this prospective,
multicentre cohort study, we consecutively recruited wom
19 y, and the USA) to assemble an international
multicentre cohort.
20 We did a population-based,
multicentre,
cohort study at five international radiosur
21 tive impairment (MCI) from single-centre and
multicentre cohorts in Europe and North America: the Eur
22 derived from four independent, prospective,
multicentre data sources, including data from December,
23 We used a large
multicentre dataset of 441 patients from the UK, USA, Ja
24 COLDICE was a prospective,
multicentre,
diagnostic accuracy study investigating dia
25 In this
multicentre double-blind randomized clinical trial, we i
26 We did two parallel, investigator-initiated,
multicentre,
double-blind randomised, controlled trials
27 We did a 24-month,
multicentre,
double-blind, double-dummy phase 3 trial in
28 This
multicentre,
double-blind, parallel-arm, randomised cont
29 In this randomised,
multicentre,
double-blind, phase 3 non-inferiority study
30 We did a
multicentre,
double-blind, phase 3, randomised controlle
31 TEAMM was a prospective,
multicentre,
double-blind, placebo-controlled randomised
32 The PANDA study was a pragmatic,
multicentre,
double-blind, placebo-controlled randomised
33 We did a
multicentre,
double-blind, placebo-controlled study (RES
34 CT 1 and IMPACT 2 were identically designed,
multicentre,
double-blind, placebo-controlled, non-infer
35 MifeMiso was a
multicentre,
double-blind, placebo-controlled, randomise
36 This
multicentre,
double-blind, placebo-controlled, randomise
37 In this
multicentre,
double-blind, randomised phase 3 trial (JAD
38 We did a
multicentre,
double-blind, randomised placebo-controlled
39 AFFIRM-AHF was a
multicentre,
double-blind, randomised trial done at 121
40 In this phase 3,
multicentre,
double-blind, randomised, comparator-contro
41 PACIFIC is an ongoing, international,
multicentre,
double-blind, randomised, controlled, phase
42 This
multicentre,
double-blind, randomised, controlled, phase
43 We conducted two identically designed,
multicentre,
double-blind, randomised, non-inferiority,
44 For this
multicentre,
double-blind, randomised, placebo-controlle
45 This
multicentre,
double-blind, randomised, placebo-controlle
46 In the
multicentre,
double-blind, randomised, placebo-controlle
47 We did a
multicentre,
double-blind, randomised, placebo-controlle
48 HPTN 077 was a
multicentre,
double-blind, randomised, placebo-controlle
49 We did a
multicentre,
double-blind, randomised, placebo-controlle
50 ORATORIO was an international,
multicentre,
double-blind, randomised, placebo-controlle
51 In this
multicentre,
double-blind, response-adaptive, randomised
52 follow-up assessment at age 6-10 years of a
multicentre European birth cohort based was undertaken u
53 Within the two-stratum, open-label,
multicentre,
factorial randomised TRACT trial, children
54 laxis (LPEP) programme was an international,
multicentre feasibility study implemented within the lep
55 We did a
multicentre,
futility-design, randomised, placebo-contro
56 In the
multicentre GENetic Frontotemporal dementia Initiative (
57 The
multicentre,
international ADDITION-Europe study investi
58 In this retrospective,
multicentre,
international cohort study, we compared out
59 This study was a retrospective,
multicentre,
international study in patients carrying th
60 mapping data from a prospective, open-label,
multicentre,
international study to investigate the infl
61 Act.In.Sarc is a phase 2-3 randomised,
multicentre,
international trial.
62 We did a
multicentre,
international, dose-confirmation and dose-e
63 We did a
multicentre,
international, retrospective cohort study o
64 CSF samples from patients in two
multicentre longitudinal studies (ADNI, n = 619; BioFIND
65 In this retrospective,
multicentre,
longitudinal, cohort study, patients who ha
66 CENTER-TBI) China registry is a prospective,
multicentre,
longitudinal, observational study done in 5
67 EHVA T01 is a
multicentre,
MAMS, double-blind, phase 1 and 2 trial tha
68 Within a
multicentre,
multi-vendor trial we established a method
69 GO30140 is an open-label,
multicentre,
multiarm, phase 1b study that enrolled pati
70 We did a
multicentre,
multicohort, open-label, phase 1b trial (IV
71 We did a
multicentre,
multigroup, phase 2 trial to evaluate the a
72 SADAL was a
multicentre,
multinational, open-label, phase 2b study d
73 TRINOVA-3, a
multicentre,
multinational, phase 3, double-blind study,
74 CTE pathology was rare in a large
multicentre national dataset, and when present, was acco
75 The interim analysis of the
multicentre New EPOC trial in patients with resectable c
76 This
multicentre,
non-blinded, randomised controlled trial wa
77 RTOG 1016 was a randomised,
multicentre,
non-inferiority trial at 182 health-care ce
78 We did an open-label,
multicentre,
non-inferiority trial of patients aged 15 y
79 This randomised, controlled, double-blind,
multicentre,
non-inferiority, phase 3 study was undertak
80 Ca, a randomised, open-label, international,
multicentre,
non-inferiority, phase 3 study, was done ac
81 In this prospective,
multicentre,
non-inferiority, randomised controlled tria
82 ID-19 Collaboration (TERAVOLT) registry is a
multicentre observational study composed of a cross-sect
83 d patients recruited to a UK hospital-based,
multicentre observational study of adults with imaging c
84 RRMS patients who initiated FTY in a 2-year
multicentre observational study, 36 were classified as '
85 In this prospective,
multicentre observational study, we analysed admissions
86 es as a post hoc analysis from a prospective
multicentre observational study.
87 c Lateral Sclerosis) study is a prospective,
multicentre,
observational study of first-degree relativ
88 HepFREE was a
multicentre,
open, cluster-randomised controlled trial i
89 This
multicentre,
open-label extension (OLE) trial enrolled p
90 ELEVATE TN is a global, phase 3,
multicentre,
open-label study in patients with treatment
91 We did a
multicentre,
open-label, non-inferiority, two-group rand
92 We did a
multicentre,
open-label, non-randomised, single-arm phas
93 SONICS is a phase 3,
multicentre,
open-label, non-randomised, single-arm stud
94 -iron-based phosphate binders (control) in a
multicentre,
open-label, parallel-design.
95 In this
multicentre,
open-label, partially randomised, phase 2b
96 The
multicentre,
open-label, phase 1-2 AG221-C-001 trial enr
97 iMATRIX was a
multicentre,
open-label, phase 1-2 trial of patients (ag
98 In this
multicentre,
open-label, phase 1/2 trial, patients with
99 The MEDIOLA trial is a
multicentre,
open-label, phase 1/2, basket trial of durv
100 In this multi-arm,
multicentre,
open-label, phase 1b study, we enrolled adu
101 In this
multicentre,
open-label, phase 1b trial following a 3 +
102 In this
multicentre,
open-label, phase 2 study done at 30 sites
103 In this randomised,
multicentre,
open-label, phase 2 study done in 39 outpat
104 The aim of this
multicentre,
open-label, phase 2 study was to compare ri
105 We did a randomised,
multicentre,
open-label, phase 3 study at 102 hospitals
106 In this randomised,
multicentre,
open-label, phase 3 study, 466 patients rec
107 Our study was designed as a
multicentre,
open-label, phase 3, randomised controlled
108 In this
multicentre,
open-label, phase 3, randomised controlled
109 IMblaze 370 is a
multicentre,
open-label, phase 3, randomised, controlled
110 In this 104-week international,
multicentre,
open-label, phase 3b randomised controlled
111 CARD was a randomised,
multicentre,
open-label, phase 4 study involving 62 clin
112 nged Efficacy open-Label (COMPEL) study is a
multicentre,
open-label, prospective study assessing the
113 In a
multicentre,
open-label, randomised controlled trial acr
114 We did a
multicentre,
open-label, randomised controlled trial at
115 In this parallel-group,
multicentre,
open-label, randomised controlled trial in
116 In this
multicentre,
open-label, randomised trial, we recruited
117 We did a
multicentre,
open-label, randomised, controlled phase 3
118 We did a
multicentre,
open-label, randomised, controlled trial in
119 New EPOC was a
multicentre,
open-label, randomised, controlled, phase 3
120 RMS 2005 was a
multicentre,
open-label, randomised, controlled, phase 3
121 In this
multicentre,
open-label, randomised, phase 2 study, 11 d
122 This
multicentre,
open-label, randomised, phase 3 trial, was
123 This phase 4,
multicentre,
open-label, randomized control trial enroll
124 In this phase 3,
multicentre,
open-label, repeat-dose study done in 33 ce
125 We did a
multicentre,
open-label, single-arm, dose-confirmation a
126 In this
multicentre,
open-label, single-arm, multicohort, phase
127 In this
multicentre,
open-label, single-arm, phase 2 study (L-MI
128 QUADRA was a
multicentre,
open-label, single-arm, phase 2 study that
129 In two identically designed,
multicentre,
open-label, single-arm, phase 3 trials (one
130 This pragmatic, parallel-group,
multicentre,
open-label, two-arm, randomised superiority
131 In this phase 3,
multicentre,
open-label, two-stage study, patients aged
132 sis treatment, we performed a retrospective,
multicentre optical coherence tomography study to longit
133 ndent small-colony variants, was common in a
multicentre paediatric population with cystic fibrosis a
134 In this
multicentre,
parallel group, randomised controlled trial
135 We conducted a pragmatic,
multicentre,
parallel randomised controlled trial in 5 D
136 In this international,
multicentre,
parallel, open-label trial, we randomly ass
137 MERGE, a
multicentre,
parallel, randomised controlled trial enrol
138 We did a
multicentre,
parallel, randomised, double-blind, placebo
139 In this
multicentre,
parallel-group, open-label, randomised cont
140 In a
multicentre,
parallel-group, open-label, randomised stud
141 G-ToG was a
multicentre,
parallel-group, pragmatic, randomised, non-
142 POETIC was an open-label,
multicentre,
parallel-group, randomised, phase 3 trial (
143 Two
multicentre phase 1 studies aimed to investigate the fea
144 e-blind, parallel-group, placebo-controlled,
multicentre phase 2 trial that evaluated the safety and
145 In this prospective
multicentre phase 2 trial, adult patients aged 18-75 yea
146 ouble-blind, randomised, placebo-controlled,
multicentre phase 3 trial, adults aged 18 years or older
147 paediatric or adult patients in two ongoing,
multicentre,
phase 1 clinical trials to evaluate the saf
148 We did an investigator-initiated,
multicentre,
phase 1-1b study of patients from five site
149 GEN501 was an open-label,
multicentre,
phase 1-2, dose escalation and expansion st
150 We did this single-arm,
multicentre,
phase 1b-2 trial in 11 centres based in fiv
151 SIRIUS was an open-label,
multicentre,
phase 2 study done in Canada, Spain, and th
152 Pediatric Brain Tumor Consortium performed a
multicentre,
phase 2 study in patients with paediatric l
153 In this randomised, open-label,
multicentre,
phase 2 study, adult patients (aged >=18 ye
154 We did a
multicentre,
phase 2 trial of axitinib given on an indiv
155 This single-arm,
multicentre,
phase 2 trial was done in 19 European acade
156 We did a
multicentre,
phase 2/3, randomised, double-blind, placeb
157 In this parallel-group, double-blind,
multicentre,
phase 2b, randomised placebo-controlled tri
158 iority, randomised (1:1 with blocks of six),
multicentre,
phase 3 clinical trial comparing fully oral
159 This randomised, controlled,
multicentre,
phase 3 study was done across 44 specialist
160 This was a randomised, open-label,
multicentre,
phase 3 trial done at ten centres in Canada
161 In this randomised, double-blind,
multicentre,
phase 3 trial, patients aged 18 years or ol
162 In this Children's Oncology Group,
multicentre,
phase 3 trial, patients were enrolled in fo
163 In this
multicentre,
phase 3, open-label, two-part study, we enr
164 In this
multicentre,
phase 3, randomised trial, untreated patien
165 FAST-Forward is a
multicentre,
phase 3, randomised, non-inferiority trial
166 is randomised, double-blind, parallel-group,
multicentre placebo-controlled trial was done at 22 hosp
167 Our
multicentre,
pragmatic randomised controlled trial was d
168 confirmed Parkinson's were recruited to this
multicentre,
pragmatic, investigator blind, individually
169 We did a
multicentre,
pragmatic, parallel-group, randomised contr
170 This
multicentre,
pragmatic, randomised controlled trial was
171 We did a
multicentre,
pragmatic, stepped-wedge cluster-randomised
172 In this
multicentre,
pragmatic, three-arm, superiority randomise
173 d healthy controls, recruited as part of the
multicentre prospective Canadian Pediatric Demyelinating
174 arge UK population-based cohort, the largest
multicentre prospective clinico-genetic incident study i
175 A
multicentre prospective cohort in five maternities in Br
176 In this large
multicentre prospective cohort study of 196 patients wit
177 Multicentre prospective double-blind randomized controll
178 Blood Pressure After Endovascular Treatment
multicentre prospective registry.
179 We did a
multicentre,
prospective observational cohort study.
180 A
multicentre,
prospective, and single blind study was per
181 We conducted a
multicentre,
prospective, observational study (PERFECT-t
182 In this
multicentre,
prospective, observational study, HIV-posit
183 In this
multicentre,
prospective, observational, cohort study, w
184 We did a
multicentre randomised controlled trial (IMAGINE) in 11
185 We conducted a
multicentre randomised trial in 5 maternity units (4 in
186 SUMS was a pragmatic,
multicentre,
randomised controlled superiority trial of
187 In this open-label, phase 2,
multicentre,
randomised controlled trial (EuLITE), we re
188 secondary care IBD centres in the UK into a
multicentre,
randomised controlled trial (RCT, ASTIClite
189 UKSTAR was a pragmatic, superiority,
multicentre,
randomised controlled trial done at 39 hosp
190 RATULS was a pragmatic,
multicentre,
randomised controlled trial done at four UK
191 In this parallel-group, non-masked,
multicentre,
randomised controlled trial done in 46 mate
192 investigator-driven extension follow-up of a
multicentre,
randomised controlled trial done in 85 hosp
193 estigator-driven extension of follow-up of a
multicentre,
randomised controlled trial done in 85 hosp
194 VAPrapid2 was a
multicentre,
randomised controlled trial in patients adm
195 CALERIE was a phase 2,
multicentre,
randomised controlled trial in young and mi
196 This double-blind,
multicentre,
randomised controlled trial of co-careldopa
197 SPRINT was an open-label,
multicentre,
randomised controlled trial undertaken at 1
198 and safety substudies within the open-label,
multicentre,
randomised ODYSSEY trial (NCT02259127) of c
199 We did a double-blind,
multicentre,
randomised placebo-controlled trial at 33 h
200 We did a prospective, open-label,
multicentre,
randomised trial in 36 European centres.
201 DEEP-2 was a phase 3,
multicentre,
randomised trial in paediatric patients (ag
202 We did a prospective, double-blind,
multicentre,
randomised trial to assess treatment with o
203 We did a
multicentre,
randomised, blinded, placebo-controlled, 40
204 This
multicentre,
randomised, controlled cross-over trial was
205 We did an open-label,
multicentre,
randomised, controlled non-inferiority tria
206 In this
multicentre,
randomised, controlled study, we recruited
207 This phase 2, open-label,
multicentre,
randomised, controlled trial was undertaken
208 We did a
multicentre,
randomised, controlled, open-label, non-inf
209 KEYNOTE-006 was an open-label,
multicentre,
randomised, controlled, phase 3 study done
210 BIG 3-07/TROG 07.01 is an international,
multicentre,
randomised, controlled, phase 3 trial evalu
211 This phase 3,
multicentre,
randomised, double-blind, active-controlled
212 We did a
multicentre,
randomised, double-blind, phase 2 study for
213 This is a
multicentre,
randomised, double-blind, phase 3 trial don
214 CONQUER was a
multicentre,
randomised, double-blind, placebo-controlle
215 In this
multicentre,
randomised, double-blind, placebo-controlle
216 This
multicentre,
randomised, double-blind, placebo-controlle
217 In this
multicentre,
randomised, double-blind, placebo-controlle
218 LIBERTY NP SINUS-52 were two multinational,
multicentre,
randomised, double-blind, placebo-controlle
219 In this phase 2
multicentre,
randomised, double-blind, placebo-controlle
220 -term Odanacatib Fracture Trial (LOFT) was a
multicentre,
randomised, double-blind, placebo-controlle
221 This
multicentre,
randomised, double-blind, placebo-controlle
222 REWIND was a
multicentre,
randomised, double-blind, placebo-controlle
223 This
multicentre,
randomised, double-blind, placebo-controlle
224 We performed a
multicentre,
randomised, double-blind, placebo-controlle
225 We did a
multicentre,
randomised, open label, blinded outcome, co
226 We did a
multicentre,
randomised, open-label trial, with blinded
227 ALCYONE was a
multicentre,
randomised, open-label, active-controlled,
228 t Children's Oncology Group and NRG Oncology
multicentre,
randomised, open-label, phase 2 trial, we e
229 IMpower130 was a
multicentre,
randomised, open-label, phase 3 study done
230 iLLUMINATE is a
multicentre,
randomised, open-label, phase 3 trial done
231 CLL14 is a
multicentre,
randomised, open-label, phase 3 trial done
232 In this 52-week,
multicentre,
randomised, open-label, phase 3a trial, we
233 A
multicentre,
randomised, open-label, superiority trial w
234 We did an open-label,
multicentre,
randomised, phase 2 trial at six hospitals
235 ICON8 was an international,
multicentre,
randomised, phase 3 trial done across 117 h
236 This
multicentre,
randomised, phase 3 trial took place at nin
237 Further studies with
multicentre randomized controlled trials and larger popu
238 PORTAS-3 was a
multicentre,
randomized, controlled, parallel-group supe
239 Data of a
multicentre,
randomized-controlled trial (SECURE-trial)
240 an ongoing, phase 2, open-label, single-arm,
multicentre,
Rare Oncology Agnostic Research (ROAR) bask
241 ZUMA-1 is a single-arm,
multicentre,
registrational trial at 22 sites in the USA
242 We did a retrospective,
multicentre registry study using a dataset from the IWWD
243 A retrospective,
multicentre,
registry-based study was conducted based on
244 There is a need for
multicentre research on vertebral radiotherapy dose dist
245 This
multicentre,
retro-prospective real-world study evaluate
246 A multinational,
multicentre retrospective cohort study, conducted in 20
247 In this 4 year
multicentre retrospective observational study, all clini
248 lation after Cardioembolic stroke study is a
multicentre retrospective study across that pooled data
249 We did a
multicentre,
retrospective cohort study including oncolo
250 In this international,
multicentre,
retrospective cohort study, we included con
251 We did a
multicentre,
retrospective, cohort study in collaboratio
252 This
multicentre,
retrospective, cohort study included paedia
253 differences across and within syndromes in a
multicentre sample of adult epilepsy patients.
254 Our studies used a
multicentre,
single-arm design at 54 sites in Australia,
255 This was an open-label,
multicentre,
single-arm phase 2 trial done at 18 hospita
256 The TRILUMINATE trial is a prospective,
multicentre,
single-arm study in 21 sites in Europe and
257 We undertook a prospective,
multicentre,
single-arm, open-label study in adults aged
258 We did a
multicentre,
single-arm, phase 2 trial at eight cancer c
259 This open-label,
multicentre,
single-arm, phase 2 trial was done at three
260 We did a
multicentre,
single-arm, two-stage, phase 2 trial in pat
261 In this parallel,
multicentre,
single-blind, randomised controlled trial,
262 We did a
multicentre,
single-blinded, randomised controlled trial
263 nagement of the practical laboratory part of
multicentre studies (e.g. import of drawing schemes and
264 Comprehensive, systematic,
multicentre studies are needed to characterise sleep dis
265 of patients with cancer and data from large,
multicentre studies to support this assumption are scarc
266 SIMPLIFY and D3FEAT are international,
multicentre studies which recruited participants with re
267 uster randomised trials, with robust SEs for
multicentre studies) for each trial, and then pooled the
268 did a prospective, randomised, single-blind,
multicentre study (TALENT) across 23 centres in Europe (
269 This large retrospective
multicentre study compared cross-sectional CSF NfL level
270 This large
multicentre study documents the high phenoconversion rat
271 Retrospective cross-sectional international
multicentre study including patients with HIV mono-infec
272 Results of a phase III prospective
multicentre study of blue light flexible cystoscopy (BLF
273 ommissural, and projection fibres in a large
multicentre study of epilepsy.
274 In this ongoing
Multicentre Study of Self-harm in England, the study pop
275 ve, observational, controlled, international
multicentre study of the NILS cohort.
276 Prospective,
multicentre study on adult patients with microbiological
277 This prospective, double-blind, phase 3
multicentre study randomly assigned patients with migrai
278 A retrospective
multicentre study was performed in IBD patients who fail
279 This randomised, double-blind,
multicentre study with identical placebo as a comparator
280 n idiopathic REM sleep behaviour disorder: a
multicentre study' by Postuma et al. (doi:10.1093/brain/
281 In this
multicentre study, we aimed to assess the cortical micro
282 In this retrospective,
multicentre study, we assessed the outcomes for adult pa
283 agmatic, investigator-initiated, open-label,
multicentre study.
284 lidate our previous findings in women from a
multicentre study.
285 intracerebral implantation is feasible in a
multicentre study.
286 ential measures of therapeutic response in a
multicentre study.
287 26), the independent validation set (Chinese
multicentre study; 428 patients treated between Jan 1, 2
288 This randomised, open-label, superiority
multicentre,
three-arm, parallel group trial was done in
289 ho were enrolled in the prospective RenalRIP
multicentre trial (validation cohort) and who were rando
290 andomised, double-blind, placebo-controlled,
multicentre trial at ten hospitals in Hubei, China.
291 , double-blind, phase 3, placebo-controlled,
multicentre trial compared once-daily subcutaneous admin
292 The Streamline L trial was a prospective,
multicentre trial done in 16 hospitals in England.
293 The Streamline C trial was a prospective,
multicentre trial done in 16 hospitals in England.
294 -5,6 was a phase 3b, single-arm, open-label,
multicentre trial done in 24 hospitals or clinics in Eur
295 andomised, double-blind, placebo-controlled,
multicentre trial with an adaptive design was done in 32
296 More large, well-designed
multicentre trials are needed to support the conclusion
297 genesis and are currently being evaluated in
multicentre trials.
298 BRIGHTE (NCT02362503) is an ongoing
multicentre,
two-cohort, phase 3 trial, done at 108 cent
299 This was a
multicentre United Kingdom study conducted in secondary
300 In this retrospective analysis and
multicentre validation study, we used paraffin-embedded